Abstract
Abstract
Purpose
To evaluate the efficacy and long-term safety (up to 108 months) of treatment with Dienogest in patients with endometriosis.
Methods
Patients with chronic pelvic pain endometriosis-related were enrolled in this observational study from June 2012 to July 2021. The patients enrolled took Dienogest 2 mg as a single daily administration. Group B of long-term therapy patients (over 15 months) were compared with group A of short-term therapy patients (0–15 months). The effects of the drug on pain variation were assessed using the VAS scale and endometriomas dimensions through ultrasonographic evaluation. Furthermore, has been valuated the appearance of side effects and the effect of the drug on bone metabolism by performing MOC every 24 months in group B.
Results
157 patients were enrolled. The mean size of the major endometrioma progressively decreased from 33.2 mm (29.4–36.9) at T0 to 7 mm (0–15.8) after 108 months of treatment. We found a significant improvement in dysmenorrhea, dyspareunia, dyschezia and non-cyclic pelvic pain. As for the side effects, both groups complained menstrual alterations present in 22.9%. In 27.6% of group B, osteopenia was found. Group B had a higher percentage statistically significant of side effects such as headaches, weight gain and libido reduction compared to group A. 2
Conclusion
Long-term therapy with Dienogest has proven effective in controlling the symptoms of the disease and reducing the size of endometriomas, with an increase in the positive effects related to the duration of the intake and in the absence of serious adverse events. Study approved by the "Palermo 2" Ethics Committee on July 2, 2012 No. 16.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,General Medicine
Reference41 articles.
1. Mehedintu C, Plotogea MN, Ionescu S, Antonovici M (2014) Endometriosis still a challenge. J Med Life 7(3):349–357
2. Barcena de Arellano ML, Gericke J, Reichelt U, Okuducu AF, Ebert AD, Chiantera V, Schneider A, Mechsner S (2011) Immunohistochemical characterization of endometriosis-associated smooth muscle cells in humanperitoneal endometriotic lesions. Hum Reprod 26:2721–2730. https://doi.org/10.1093/humrep/der253
3. Mounsey A, Wilgus A, Slawson D (2018) Diagnosis and management of endometriosis. Am Fam Phys 74:594–600
4. Judge LC, Kao LC (2004) Endometriosis. Lancet 364(9447):1789–1799. https://doi.org/10.1016/S0140-6736(04)17403-5
5. Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, Bush D, Kiesel L, Tamimi R, Sharpe-Timms KL, Rombauts L, Giudice LC, World Endometriosis Society Sao Paulo Consortium (2017) World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 32(2):315–324. https://doi.org/10.1093/humrep/dew293
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献